Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | METAP1 | P53582 | 2/20 | 0.45 |
| ▸ | BCL2 | P10415 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | DRD5 | P21918 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL393640 | 0.88 | ALDH1A1 (0.49) | METAP1BCL2PDE3BPDE3AALDH1A1 | |
| SCHEMBL29940664 | 0.88 | ALDH1A1 (0.49) | METAP1BCL2PDE3BPDE3AALDH1A1 | |
| SCHEMBL23950370 | 0.82 | AR (0.44) | ARKDM1AMETAP1BCL2PARP1 | |
| SCHEMBL29051722 | 0.78 | PDE3B (0.49) | ARKDM1AMETAP1PARP1PDE3B | |
| SCHEMBL898418 | 0.77 | MAPK14 (0.43) | METAP1SMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL21226516 | 0.76 | KDM1A (0.43) | ARKDM1ABCL2PARP1DRD2 | |
| SCHEMBL20061150 | 0.76 | KDM1A (0.43) | ARKDM1ABCL2PARP1SMN1; SMN2 | |
| SCHEMBL28413224 | 0.76 | METAP1 (0.47) | METAP1PDE3BPDE3AMAOBDRD2 | |
| SCHEMBL27287933 | 0.76 | TDP1 (0.41) | METAP1PARP1 | |
| SCHEMBL30476321 | 0.76 | METAP1 (0.47) | METAP1PDE3BPDE3AMAOBDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114327-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-04-10 | — | — | US | disclosed |
| US-20230398096-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230398096-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230398096-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-29 | — | — | US | disclosed |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-29 | — | — | US | disclosed |
| US-20210052550-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-02-25 | — | — | US | disclosed |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2012-04-05 | — | — | US | disclosed |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2012-04-05 | — | — | US | disclosed |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2012-04-05 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| WO-2010143664-A1 | TETRACYCLIC COMPOUND | 中外製薬株式会社 (JP) | 2010-12-16 | — | — | WO | disclosed |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI CO., LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| EP-1577288-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Eisai Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142119-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | AR 1136/4885KDM1A 1270/4885METAP1 2376/4885 |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ESR1, GPER1, ESR2 | AR 10/4885KDM1A 286/4885METAP1 3534/4885 |
| US-20250114327-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | ALK, ALPI, TTR | AR 1421/4885KDM1A 1938/4885METAP1 3436/4885 |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | AR 1136/4885KDM1A 1270/4885METAP1 2376/4885 |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | AR 1136/4885KDM1A 1270/4885METAP1 2376/4885 |
| US-20230398096-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | ALK, ALPI, TTR | AR 1421/4885KDM1A 1938/4885METAP1 3436/4885 |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | BRCA1, BCR, RCC1 | AR 22/4885KDM1A 332/4885METAP1 3160/4885 |
| US-20210052550-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | ALK, ALPI, TTR | AR 1421/4885KDM1A 1938/4885METAP1 3436/4885 |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | ESR1, GPER1, ESR2 | AR 9/4885KDM1A 434/4885METAP1 3842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.